Genetics

Horizon Discovery Expands Cell-Based CRISPR Screening Services

Friday, April 3, 2020 - 3:12pm

Horizon Discovery Group plc (LSE: HZD) (Horizon, the Company or the Group), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the addition of an arrayed CRISPR knockout screening service for primary human B cells to its cell-based screening services.

Key Points: 
  • Horizon Discovery Group plc (LSE: HZD) (Horizon, the Company or the Group), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the addition of an arrayed CRISPR knockout screening service for primary human B cells to its cell-based screening services.
  • Terry Pizzie, CEO, Horizon Discovery said: The interest in harnessing the immune system for effective therapies continues to grow, with the global cell therapy market predicted to reach $8.21bn by 2025*.
  • Expanding our services to encompass screening of both primary T and B cells is another example of our commitment to apply decades of gene editing experience in support of drug discovery and development for the treatment of human disease.
  • For further information about Horizons cell-based screening services, please visit: https://horizondiscovery.com/navigation/screening/functional-genomic-screening

Global Genetic Testing Market Outlook to 2022 by Application, Disease & Geography - ResearchAndMarkets.com

Friday, April 3, 2020 - 2:21pm

The "Global Genetic Testing Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genetic Testing Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.
  • Growing awareness about genetic testing, technological advances in genetic sequencing, and rising incidences of genetic diseases especially cancer are some of the major factors propelling the genetic testing market.
  • Global Genetic Testing Market Outlook 2022 provides a detailed analysis of the genetic testing market.
  • 1) Based on the application, the genetic testing market is divided into Diagnostic Testing, Newborn Screening, Prenatal Testing, Carrier Screening, and Others.

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Friday, April 3, 2020 - 12:00pm

Vesting of each option award is subject to continued service with AVROBIO by the employee through the applicable vesting dates.

Key Points: 
  • Vesting of each option award is subject to continued service with AVROBIO by the employee through the applicable vesting dates.
  • Our mission is to free people from a lifetime of genetic disease with a single dose of gene therapy.
  • AVROBIO is powered by the plato gene therapy platform, our foundation designed to scale gene therapy worldwide.
  • AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic

Thursday, April 2, 2020 - 2:00pm

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders.
  • The companys platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients contending with rare genetic diseases.
  • Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition.
  • Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes.

Applied DNA and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5th Candidate

Thursday, April 2, 2020 - 1:18pm

Applied DNA Sciences Inc. (NASDAQ: APDN) (Applied DNA or the Company) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, and Takis Biotech (Takis), a company focused on the development of cancer vaccines and founded by scientists from Merck Research Laboratories, today announce an expansion of their COVID-19 vaccine development program to include a fifth vaccine candidate.

Key Points: 
  • Applied DNA Sciences Inc. (NASDAQ: APDN) (Applied DNA or the Company) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, and Takis Biotech (Takis), a company focused on the development of cancer vaccines and founded by scientists from Merck Research Laboratories, today announce an expansion of their COVID-19 vaccine development program to include a fifth vaccine candidate.
  • Dr. James Hayward, president and CEO of Applied DNA, stated, With the addition of a fifth candidate, we have more arrows in our quiver to enhance our probability of success.
  • The new potential candidate may facilitate a productive immune response, while minimizing mechanisms known to have potential negative effects on the infection.
  • Concurrent with the Takis animal trials, Applied DNA will prepare for cGMP production of selected vaccine candidate(s) to support human trials scheduled to begin this fall.

Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer

Thursday, April 2, 2020 - 1:00pm

Our initial data on the combination of PADCEV and pembrolizumab in previously untreated patients who could not receive cisplatin are encouraging.

Key Points: 
  • Our initial data on the combination of PADCEV and pembrolizumab in previously untreated patients who could not receive cisplatin are encouraging.
  • The EV-302 trial is evaluating the combination of PADCEV and pembrolizumab with or without chemotherapy versus chemotherapy alone in patients with previously untreated locally advanced or metastatic urothelial cancer.
  • PADCEV was approved under the FDAs Accelerated Approval Program based on tumor response rate.
  • Hyperglycemia occurred in patients treated with PADCEV, including death and diabetic ketoacidosis (DKA), in those with and without pre-existing diabetes mellitus.

Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimer’s Pathology at Advances in Alzheimer’s and Parkinson’s Therapies Virtual Focus Meeting 2020

Thursday, April 2, 2020 - 1:00pm

The data is being presented this week as part of the Advances in Alzheimers and Parkinsons Disease (AAT-AD/PD) Focus Meeting 2020, which was converted to a virtual meeting due to the COVID-19 pandemic and is being held April 2-5.

Key Points: 
  • The data is being presented this week as part of the Advances in Alzheimers and Parkinsons Disease (AAT-AD/PD) Focus Meeting 2020, which was converted to a virtual meeting due to the COVID-19 pandemic and is being held April 2-5.
  • Over the past several years, Cortexyme and scientists around the world have been publishing evidence on the role of P. gingivalis in Alzheimers disease.
  • P. gingivalis is best known in published literature as the keystone pathogen in the development of periodontal disease.
  • The data presented today adds to the preclinical and clinical evidence supporting our approach to this devastating disease.

Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

Thursday, April 2, 2020 - 12:30pm

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that management will participate in the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day on Friday, April 3, 2020.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that management will participate in the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day on Friday, April 3, 2020.
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders.
  • The companys platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients contending with rare genetic diseases.
  • Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition.

Castle Biosciences Appoints Miles Harrison to Board of Directors

Thursday, April 2, 2020 - 12:00pm

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Miles Harrison has been appointed to the board of directors, effective immediately, expanding the size of the board to eight members.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Miles Harrison has been appointed to the board of directors, effective immediately, expanding the size of the board to eight members.
  • Mr. Harrison will stand for election for a three-year term at Castle Biosciences 2020 Annual Meeting of Stockholders.
  • We are pleased to welcome Miles to our board, said Derek Maetzold, president and chief executive officer of Castle Biosciences.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005133/en/

ERS Genomics and Axxam Announce CRISPR/Cas9 License Agreement to Enhance Discovery Services

Thursday, April 2, 2020 - 11:31am

ERS Genomics Limited (ERS Genomics), which was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Axxam S.p.A. (Axxam), a leading discovery biology company, today announced the signing of a license agreement granting Axxam access to ERS Genomics' CRISPR-Cas9 patent portfolio, to support Axxam's integrated discovery service platform.

Key Points: 
  • ERS Genomics Limited (ERS Genomics), which was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Axxam S.p.A. (Axxam), a leading discovery biology company, today announced the signing of a license agreement granting Axxam access to ERS Genomics' CRISPR-Cas9 patent portfolio, to support Axxam's integrated discovery service platform.
  • The platform will applied across Axxams integrated discovery services, in fields such as pharmaceuticals, crop protection, animal health, and food and beverages.
  • We are proud to add Axxam to our growing list of partners applying CRISPR-Cas9 technology to their service offerings, said Eric Rhodes, CEO of ERS Genomics.
  • Axxam's discovery services cover a wide array of fields and we look forward to seeing how its use of CRISPR-Cas9 impacts these areas."